Data released from the Dialysis Outcomes and Practice Patterns Study Program show use of the calcimimetic etelcalcetide has increased to 6% among patients on in-center hemodialysis in the United States, including use by 20% of patients treated at small-chain and independent providers.
The findings are part of the latest DOPPS research which was presented at a web conference. A link to the slides from the conference and an audio recording is available at https://www.dopps.org/dpm/PapersAndNews.aspx.
The data also show use of iron-containing phosphate binders (sucroferric oxyhydroxide and ferric citrate) has increased to 12% as of August 2019. However, average phosphorus levels have increased from 5.3 mg/dl in August 2017 to 5.5 mg/dl in August 2019.
Bruce Robinson, MD, MS, FACP, scientific director of the DOPPS Program, also shared data suggesting that many patients on hemodialysis with depressive symptoms do not have clinically diagnosed depression.
“These findings support the value of the recent CMS Quality Incentive Program (QIP) clinical depression screening and follow-up reporting measure,” Robinson said in a press release.
DOPPS collects its information through the Dialysis Practice Monitor, which generates data presented on more than 1,500 regularly updated charts, figures and data tables from more than 9,000 patients receiving chronic in-center hemodialysis in a national sample of more than 160 dialysis facilities.
During the web conference, Doug Fuller, MS, presented an overview of the most recent U.S. hemodialysis practice trends through August 2019, including the latest on mineral and bone metabolism and anemia management, treatment time and ultrafiltration rate. Miriam Godwin, health policy analyst at the National Kidney Foundation, presented a discussion on regulatory issues and rulemaking, including the latest policy updates related to Advancing American Kidney Health.
Disclosure: Robinson reports no relevant financial disclosures.